NASDAQ
Interpace Biosciences, Inc. (IDXG) has a free cash flow growth of -93.24% as of Friday, May 29, 2026. This represents a 186.92% decrease compared to its 12-month average of 107.26%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.